|
US5852188A
(en)
|
1990-01-11 |
1998-12-22 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having chiral phosphorus linkages
|
|
EP0464638B1
(de)
|
1990-07-02 |
1997-04-02 |
Hoechst Aktiengesellschaft |
Oligonucleotid-analoge mit terminalen 3'-3'-bzw. 5'-5'-Internucleotidverknüpfungen
|
|
US5512668A
(en)
|
1991-03-06 |
1996-04-30 |
Polish Academy Of Sciences |
Solid phase oligonucleotide synthesis using phospholane intermediates
|
|
TW323284B
(https=)
|
1992-03-23 |
1997-12-21 |
Novartis Ag |
|
|
US5216168A
(en)
|
1992-04-01 |
1993-06-01 |
G. D. Searle & Co. |
2- and 3- amino and azido derivatives of 1,5-iminosugars
|
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
|
US6617442B1
(en)
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
|
US20030138797A1
(en)
|
2001-06-29 |
2003-07-24 |
Micrologix Biotech Inc. |
Nucleic acid-based compounds
|
|
AU2002362312A1
(en)
|
2001-09-17 |
2003-04-01 |
Mayo Foundation For Medical Education And Research |
Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof
|
|
JP4348044B2
(ja)
|
2002-02-12 |
2009-10-21 |
株式会社キラルジェン |
立体規則性の高いジヌクレオシドホスホロチオエートの製造法
|
|
US8232383B2
(en)
|
2002-02-20 |
2012-07-31 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
WO2004007718A2
(en)
|
2002-07-10 |
2004-01-22 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Rna-interference by single-stranded rna molecules
|
|
WO2004014933A1
(en)
|
2002-08-07 |
2004-02-19 |
University Of Massachusetts |
Compositions for rna interference and methods of use thereof
|
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
|
JP2005089441A
(ja)
|
2003-08-08 |
2005-04-07 |
Toudai Tlo Ltd |
立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法
|
|
WO2005023828A1
(ja)
|
2003-09-02 |
2005-03-17 |
Takeshi Wada |
リボヌクレオチド又はリボヌクレオチド誘導体の製造方法
|
|
WO2005028494A1
(ja)
|
2003-09-02 |
2005-03-31 |
Takeshi Wada |
５'-ホスフィチル化モノマーおよびh-ホスホネートオリゴヌクレオチド誘導体の製造方法
|
|
MY145571A
(en)
|
2003-12-19 |
2012-02-29 |
Ciba Holding Inc |
Fluorocarbon terminated oligo-and poly-carbonates as surface modifiers
|
|
JP4945129B2
(ja)
|
2004-01-27 |
2012-06-06 |
株式会社キラルジェン |
フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法
|
|
WO2005085272A1
(ja)
|
2004-03-05 |
2005-09-15 |
Takeshi Wada |
ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
|
|
WO2005092909A1
(ja)
|
2004-03-25 |
2005-10-06 |
Toudai Tlo, Ltd. |
立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法
|
|
ATE498685T1
(de)
|
2004-06-28 |
2011-03-15 |
Univ Western Australia |
Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
|
|
WO2006023880A2
(en)
|
2004-08-23 |
2006-03-02 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for the characterization of oligonucleotides
|
|
EP1801114B8
(de)
|
2005-11-23 |
2009-12-02 |
Roche Diagnostics GmbH |
Polynukleotid mit Phosphatmimetikum
|
|
EP2147010A1
(en)
|
2007-04-18 |
2010-01-27 |
Roche Diagnostics GmbH |
Nucleotide with an alpha-phosphate mimetic
|
|
AU2008317566B2
(en)
|
2007-10-26 |
2014-05-01 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
DK2285819T3
(da)
|
2008-04-04 |
2013-12-02 |
Isis Pharmaceuticals Inc |
Oligomere forbindelser omfattende neutralt bundne, terminale bicykliske nukleosider
|
|
AU2009238175C1
(en)
|
2008-04-15 |
2023-11-30 |
Arbutus Biopharma Corporation |
Novel lipid formulations for nucleic acid delivery
|
|
US8324366B2
(en)
|
2008-04-29 |
2012-12-04 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for delivering RNAI using lipoproteins
|
|
EP2358398A2
(en)
|
2008-10-24 |
2011-08-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
|
WO2010048549A2
(en)
|
2008-10-24 |
2010-04-29 |
Isis Pharmaceuticals, Inc. |
5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
|
|
JP5786109B2
(ja)
|
2008-10-27 |
2015-09-30 |
プロセンサ テクノロジーズ ベー．フェー． |
Ｄｕｃｈｅｎｎｅ型筋ジストロフィーｍＲＮＡ前駆体のエクソン４５の効率的なスキッピングのための方法及び手段
|
|
RU2572826C2
(ru)
|
2008-12-02 |
2016-01-20 |
Чиралджен, Лтд. |
Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
|
|
CA2750561C
(en)
|
2009-01-26 |
2017-10-10 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein c-iii expression
|
|
CA2767253A1
(en)
|
2009-07-06 |
2011-01-13 |
Ontorii, Inc. |
Novel nucleic acid prodrugs and methods of use thereof
|
|
US8927513B2
(en)
|
2009-07-07 |
2015-01-06 |
Alnylam Pharmaceuticals, Inc. |
5′ phosphate mimics
|
|
EP2479182B8
(en)
|
2009-09-16 |
2016-07-13 |
Wave Life Sciences Japan, Inc. |
Novel protecting group for synthesizing rna and derivative thereof
|
|
WO2011109427A2
(en)
|
2010-03-01 |
2011-09-09 |
Alnylam Pharmaceuticals, Inc. |
Improving the biological activity of sirna through modulation of its thermodynamic profile
|
|
US8859755B2
(en)
|
2010-03-05 |
2014-10-14 |
Chiralgen, Ltd. |
Method for preparing ribonucleoside phosphorothioate
|
|
JP2011184318A
(ja)
|
2010-03-05 |
2011-09-22 |
Univ Of Tokyo |
リボヌクレシドｈ−ボラノホスホネート
|
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
TWI541024B
(zh)
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
|
CA2812046A1
(en)
|
2010-09-15 |
2012-03-22 |
Alnylam Pharmaceuticals, Inc. |
Modified irna agents
|
|
JP5868324B2
(ja)
|
2010-09-24 |
2016-02-24 |
株式会社Wave Life Sciences Japan |
不斉補助基
|
|
JP6093924B2
(ja)
|
2010-11-30 |
2017-03-15 |
株式会社Wave Life Sciences Japan |
２’−ｏ−修飾ｒｎａ
|
|
CN107854478A
(zh)
|
2011-04-27 |
2018-03-30 |
Ionis制药公司 |
载脂蛋白ciii（apociii）表达的调节
|
|
CN103649103A
(zh)
|
2011-06-21 |
2014-03-19 |
阿尔尼拉姆医药品有限公司 |
用于抑制载脂蛋白c-iii(apoc3)基因表达的组合物与方法
|
|
US9416154B2
(en)
|
2011-07-13 |
2016-08-16 |
Merck Sharp & Dohme Corp. |
5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
|
AU2012284265B2
(en)
|
2011-07-19 |
2017-08-17 |
Wave Life Sciences Ltd. |
Methods for the synthesis of functionalized nucleic acids
|
|
EP2792746A4
(en)
|
2011-12-12 |
2015-09-16 |
Nat Cerebral & Cardiovascular Ct |
OLIGONUCLEOTIDE AND THERAPEUTIC FOR HYPERLIPIDEMIA WITH THIS AS AN ACTIVE SUBSTANCE
|
|
CN112251436A
(zh)
*
|
2012-01-27 |
2021-01-22 |
比奥马林技术公司 |
治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
|
|
EP2870246B1
(en)
|
2012-07-03 |
2019-09-11 |
BioMarin Technologies B.V. |
Oligonucleotide for the treatment of muscular dystrophy patients
|
|
CN104684923B
(zh)
|
2012-07-13 |
2018-09-28 |
株式会社新日本科学 |
手性核酸佐剂
|
|
SG11201500239VA
(en)
|
2012-07-13 |
2015-03-30 |
Wave Life Sciences Japan |
Asymmetric auxiliary group
|
|
JP6453212B2
(ja)
|
2012-07-13 |
2019-01-16 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
キラル制御
|
|
US10077443B2
(en)
|
2012-11-15 |
2018-09-18 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugates
|
|
AU2014216137B2
(en)
|
2013-02-14 |
2018-05-10 |
Ionis Pharmaceuticals, Inc. |
Modulation of Apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations
|
|
DK2991656T3
(da)
|
2013-05-01 |
2020-03-23 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
|
|
WO2015108047A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
|
WO2015108048A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
|
JPWO2015108046A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
|
|
ES2917473T3
(es)
|
2014-01-16 |
2022-07-08 |
Wave Life Sciences Ltd |
Diseño quiral
|
|
SMT201900169T1
(it)
|
2014-03-12 |
2019-05-10 |
Nippon Shinyaku Co Ltd |
Acido nucleico antisenso
|
|
PT3137605T
(pt)
|
2014-05-01 |
2020-12-18 |
Ionis Pharmaceuticals Inc |
Composições e métodos para modulação da expressão de angiopoietina de tipo 3
|
|
RU2708237C2
(ru)
|
2014-08-22 |
2019-12-05 |
Общество с ограниченной ответственностью "НооГен" |
Модифицированные олигонуклеотиды и способ их получения
|
|
HK1244843A1
(zh)
|
2014-11-17 |
2018-08-17 |
Alnylam Pharmaceuticals, Inc. |
载脂蛋白c3(apoc3)irna组合物及其使用方法
|
|
WO2016130806A2
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
SMT202000454T1
(it)
|
2015-04-03 |
2020-11-10 |
Univ Massachusetts |
Cmposti oligonucleotidici per bersagliare l'mrn della huntingtina
|
|
CN108135921B
(zh)
|
2015-07-22 |
2023-10-17 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
EP3350328A1
(en)
|
2015-09-14 |
2018-07-25 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
|
JP7511326B2
(ja)
|
2015-10-09 |
2024-07-05 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド組成物およびその方法
|
|
EP3858993A1
(en)
*
|
2015-10-09 |
2021-08-04 |
Sarepta Therapeutics, Inc. |
Compositions and methods for treating duchenne muscular dystrophy and related disorders
|
|
WO2017132669A1
(en)
|
2016-01-31 |
2017-08-03 |
University Of Massachusetts |
Branched oligonucleotides
|
|
CA3015823A1
(en)
|
2016-03-13 |
2017-09-21 |
Wave Life Sciences Ltd. |
Compositions and methods for phosphoramidite and oligonucleotide synthesis
|
|
JP2019516680A
(ja)
|
2016-05-04 |
2019-06-20 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
オリゴヌクレオチド組成物およびその方法
|
|
WO2017192679A1
(en)
|
2016-05-04 |
2017-11-09 |
Wave Life Sciences Ltd. |
Methods and compositions of biologically active agents
|
|
MA45183A
(fr)
|
2016-05-24 |
2019-04-10 |
Sarepta Therapeutics Inc |
Procédés de préparation d'oligomères morpholino de phosphorodiamidate
|
|
CN109562122A
(zh)
|
2016-06-03 |
2019-04-02 |
波涛生命科学有限公司 |
寡核苷酸、组合物及其方法
|
|
CA3029772A1
(en)
*
|
2016-07-05 |
2018-01-11 |
Biomarin Technologies B.V. |
Pre-mrna splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders
|
|
US20190330626A1
(en)
*
|
2016-07-15 |
2019-10-31 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for use in dystrophin transcript
|
|
WO2018022473A1
(en)
|
2016-07-25 |
2018-02-01 |
Wave Life Sciences Ltd. |
Phasing
|
|
RU2016138168A
(ru)
|
2016-09-26 |
2018-03-29 |
Оксфордский Университет |
Аналоги олигонуклеотидов как средства коррекции сплайсинга для лечения мышечной дистрофии дюшена
|
|
MA46905A
(fr)
|
2016-11-23 |
2019-10-02 |
Wave Life Sciences Ltd |
Compositions et procédés de synthèse de phosphoramidites et d'oligonucléotides
|
|
RU2740501C2
(ru)
|
2017-02-21 |
2021-01-14 |
Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) |
МОДИФИЦИРОВАННЫЕ ОЛИГОНУКЛЕОТИДЫ, АКТИВИРУЮЩИЕ РНКазу Н
|
|
JP2020522265A
(ja)
|
2017-06-02 |
2020-07-30 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
オリゴヌクレオチド組成物及びその使用方法
|
|
US11603532B2
(en)
|
2017-06-02 |
2023-03-14 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
US11597927B2
(en)
|
2017-06-02 |
2023-03-07 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
US11718638B2
(en)
|
2017-06-21 |
2023-08-08 |
Wave Life Sciences Ltd. |
Compounds, compositions and methods for synthesis
|
|
WO2019002237A1
(en)
|
2017-06-28 |
2019-01-03 |
Roche Innovation Center Copenhagen A/S |
METHOD OF MULTIPLE COUPLING AND OXIDATION
|
|
TW201920672A
(zh)
|
2017-08-08 |
2019-06-01 |
新加坡商波濤生命科學有限公司 |
寡核苷酸組合物及其使用方法
|
|
CN111108096A
(zh)
|
2017-09-18 |
2020-05-05 |
波涛生命科学有限公司 |
寡核苷酸制备技术
|
|
WO2019071028A1
(en)
|
2017-10-04 |
2019-04-11 |
Avidity Biosciences Llc |
NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF
|
|
EP3694530A4
(en)
|
2017-10-12 |
2021-06-30 |
Wave Life Sciences Ltd. |
COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
|
|
AR113490A1
(es)
|
2017-12-12 |
2020-05-06 |
Amgen Inc |
CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS
|
|
IL277889B2
(en)
|
2018-04-12 |
2025-01-01 |
Wave Life Sciences Ltd |
Oligonucleotide preparations and methods of using them
|
|
EP3790596A4
(en)
|
2018-05-11 |
2022-04-06 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE
|
|
TWI856973B
(zh)
|
2018-09-19 |
2024-10-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
|
SG11202105626TA
(en)
|
2018-12-06 |
2021-06-29 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
KR20210121199A
(ko)
|
2019-02-01 |
2021-10-07 |
웨이브 라이프 사이언시스 리미티드 |
올리고뉴클레오티드 조성물 및 이의 방법
|
|
CN113748116A
(zh)
|
2019-03-20 |
2021-12-03 |
波涛生命科学有限公司 |
可用于寡核苷酸制备的技术
|
|
WO2020196662A1
(ja)
|
2019-03-25 |
2020-10-01 |
国立大学法人東京医科歯科大学 |
二本鎖核酸複合体及びその使用
|
|
CA3137741A1
(en)
|
2019-04-25 |
2020-10-29 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
EP3958872A4
(en)
|
2019-04-25 |
2024-07-03 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
AU2020267775A1
(en)
|
2019-05-09 |
2021-12-02 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
CN114585737A
(zh)
|
2019-10-06 |
2022-06-03 |
波涛生命科学有限公司 |
寡核苷酸组合物及其使用方法
|
|
KR20220070324A
(ko)
|
2019-10-06 |
2022-05-30 |
웨이브 라이프 사이언시스 리미티드 |
올리고뉴클레오티드 조성물 및 이의 이용 방법
|
|
TW202138559A
(zh)
|
2019-12-16 |
2021-10-16 |
美商阿尼拉製藥公司 |
含類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法
|
|
AU2021230473A1
(en)
|
2020-03-01 |
2022-09-22 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
TW202202153A
(zh)
|
2020-03-26 |
2022-01-16 |
美商艾羅海德製藥公司 |
用於抑制ＰＮＰＬＡ３表現之ＲＮＡｉ劑、其醫藥組成物及使用方法
|
|
JP2023526975A
(ja)
|
2020-05-22 |
2023-06-26 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド組成物及びその方法
|
|
JP2023526533A
(ja)
|
2020-05-22 |
2023-06-21 |
ウェイブ ライフ サイエンシズ リミテッド |
二本鎖オリゴヌクレオチド組成物及びそれに関連する方法
|
|
EP4200616A1
(en)
|
2020-08-24 |
2023-06-28 |
Wave Life Sciences Ltd. |
Immunoassays for detecting wild type huntingtin protein and methods of treatment employing such immunoassays
|
|
WO2022046667A1
(en)
|
2020-08-24 |
2022-03-03 |
Wave Life Sciences Ltd. |
Cells and non-human animals engineered to express adar1 and uses thereof
|
|
US20230416847A1
(en)
|
2020-09-24 |
2023-12-28 |
Mayo Foundation For Medical Education And Research |
Screening platforms
|
|
IL300882A
(en)
|
2020-10-02 |
2023-04-01 |
Ionis Pharmaceuticals Inc |
Methods for reducing APOCIII expression
|
|
CN116507724A
(zh)
|
2020-11-08 |
2023-07-28 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
EP4240849A4
(en)
|
2020-11-08 |
2026-04-01 |
Wave Life Sciences Ltd |
OLIGONUCLEOTIDE COMPOSITIONS AND ASSOCIATED PROCESSES
|
|
AU2022352779A1
(en)
|
2021-09-26 |
2024-03-28 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|
|
JP2024536088A
(ja)
|
2021-09-26 |
2024-10-04 |
ウェイブ ライフ サイエンシズ リミテッド |
Ｍｅｃｐ２転写物を編集するための組成物及びその方法
|
|
CA3236136A1
(en)
|
2021-10-27 |
2023-05-04 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
EP4422645A4
(en)
|
2021-10-27 |
2025-12-03 |
Wave Life Sciences Ltd |
OLIGONUCLEOTID COMPOSITIONS AND THEIR METHODS OF USE
|
|
EP4476202A1
(en)
|
2022-02-11 |
2024-12-18 |
Wave Life Sciences Ltd. |
Stereoselective technologies for chiral compounds
|
|
IL315089A
(en)
|
2022-03-02 |
2024-10-01 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof for exon skipping
|
|
IL316178A
(en)
|
2022-04-15 |
2024-12-01 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods related thereto
|
|
CN119452084A
(zh)
|
2022-05-12 |
2025-02-14 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
JP2025526712A
(ja)
|
2022-08-11 |
2025-08-15 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド組成物及びその方法
|
|
WO2025030155A1
(en)
|
2023-08-03 |
2025-02-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods thereof
|